Efficacy

STUDY DESCRIPTION:
Utian et al: HOPE trial. Data from the Women’s Health, Osteoporosis, Progestin, Estrogen (HOPE) study: a 2-year trial of 2673 healthy, postmenopausal women (average age 53.3 years) with a uterus. This study reflects the results from the first year of the trial in the efficacy-evaluable population (n=241), which examined the effects of 3 dosage combinations of conjugated equine estrogen (CEE) therapy (including 2 lower dosages) with and without medroxyprogesterone (MPA) on vulvovaginal atrophy (VVA) and vasomotor symptoms. Within each treatment group, the number of patients included in the analyses ranged from 25 to 34 during weeks 1 through 12.2
REFERENCES:
  1. Premarin [prescribing information]. New York, NY: Pfizer Inc.; September 2018. 
  2. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75(6):1065-1079.
  3. Data on file. Pfizer Inc., New York, NY.